secwatch.observer — SEC 8-K summary
======================================

Issuer:     DYADIC INTERNATIONAL INC (DYAI)
CIK:        0001213809
Form:       8-K
Filed at:   2024-08-13T23:59:59+00:00
Accession:  0001437749-24-026398
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dyadic Q2 2024 revenue down 54% YoY to $386k; net loss $2.05M; cash $10.1M
--------------------------------------------------------------------------

- Net loss $2.045M ($0.07/share) vs $2.153M ($0.07) YoY; operating loss $2.043M.
- Cash and securities $10.1M at June 30, 2024, up from $7.3M at Dec 31, 2023.
- Partnered with Proliant Health for animal-free recombinant albumin; $500k initial payment received.
- Joint development with a Top 10 global dairy for food-grade alpha-lactalbumin.
- Avian flu H5 nanoparticle antigen shows high neutralizing antibody titers in animal studies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1213809/000143774924026398/0001437749-24-026398-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1213809/000143774924026398/dyai20240523_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-026398

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer